Supporting Primary Prevention
To eliminate unnecessary initial exposure and inappropriate prolonged prescribing of substances with abuse potential, FDA is:
- Promoting appropriate prescribing of medications with abuse potential, including opioids, stimulants, and benzodiazepines
- Exploring the need for potential new authorities for opioid approval standards
- Supporting development of alternative, nonaddictive therapies and technologies
- Evaluating innovative packaging and disposal solutions of medications with abuse potential
United States Government Partners
- Department of Health & Human Services (HHS)
- Centers for Disease Control and Prevention (CDC)
- Centers for Medicare & Medicaid Services (CMS)
- National Institutes of Health (NIH)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
FDA Activities
- Supporting Clinical Practice Guidelines for Drugs with Abuse Potential
- FDA Announces New Safety Label Changes for Opioid Pain Medicines
- External Review of FDA Regulation of Opioid Analgesics Final Report (PDF - 1.21 MB)
- SUPPORT Act Section 7024: Report to Congress on Opioid Prescribing Limits (PDF - 871 KB)
- SUPPORT Act Section 3002: Report on Evidence-Based Opioid Analgesic Prescribing Guidelines (PDF - 225 KB)
- Opioid Analgesic Drugs: Considerations for Benefit/Risk Assessment Framework (draft guidance)
- Opioid Policy Steering Committee (OPSC)
- Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use